COLLISION RELAPSE Trial

PHASE3RecruitingINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

April 24, 2023

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2028

Conditions
Colorectal CancerLiver MetastasesLiver Metastasis Colon CancerChemotherapy EffectSurgeryRecurrence
Interventions
DRUG

Neoadjuvant systemic therapy (CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B)

"Standard first line systemic treatment:~CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B~CAPOX 4x (12 weeks) FOLFOX/FOLFIRI 6x (12 weeks)~Maximum 4 cycles of CAPOX or 6 cycles of FOLFOX/FOLFIRI +/- bevacizumab regardless of the location of primary tumor or RAS/BRAF mutation"

OTHER

Repeat local treatment

"Choice of repeat local treatment is to the discretion of the local investigator, and may be selected on a per patient basis.~The safety, feasibility and preferred type of surgical resection(s) is at the discretion of the liver surgeon (whether or not combined with thermal ablation).~The safety, feasibility and preferred type of thermal ablation(s) is at the discretion of the interventional radiologist (whether or not combined with surgical resection)."

Trial Locations (1)

Unknown

RECRUITING

Amsterdam UMC, Amsterdam

All Listed Sponsors
lead

Amsterdam UMC, location VUmc

OTHER